Clinical trials: HER2

HER2 or EGFR Expressing Advanced Solid Malignancies

MAD Refractory: Solid Tumor QD w/o Break

• Completed
• Age: 18 years and older
• Phase 1

This is a continuous dosing Phase I Study of BMS-599626 in patients with HER2-expressing advanced solid malignancies.

Trial name

NCT00207012

Testing

BMS-599626

Where

2 sites in France, Spain

Volunteers

45 people

Sponsor

Bristol-Myers Squibb